DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/tx4hkf/global) has announced the addition of the "Global Non-melanoma Skin Cancer Market 2014-2018" report to their offering.
The analysts forecast the Global Non-melanoma Skin Cancer market to grow at a CAGR of 27.93 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Non-melanoma Skin Cancer market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the following segments:
- Chemotherapy, which includes drugs used in the treatment of SCC, BCC, and actinic keratosis
- Non-invasive Treatments, which include PDT, radiotherapy, cryotherapy, and laser therapy
- Elekta AB
- F. Hoffmann-la Roche Ltd.
- iCAD Inc.
- Meda AB
- Valeant Pharmaceuticals Inc.
- Varian Medical Systems Inc.
Commenting on the report, an analyst from the team said: A current trend witnessed in the Global Non-melanoma Skin Cancer market is the use of combination therapies for the treatment of non-melanoma skin cancer. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapies help in the complete removal of tumors and destruction of cancerous cells. For instance, radiation therapy may be used in combination with other therapies (chemotherapy and surgery) to treat aggressive or recurrent non-melanoma skin cancer. Patients that are non-reactive may react to combination therapy with 0.5 percent tretinoin cream with 5-FU cream.
For more information visit http://www.researchandmarkets.com/research/tx4hkf/global
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.